Across 100 patients in three Phase III studies, Vertex's Casgevy showed lasting benefits for more than five years.

The companies are also running an open-label study to evaluate the long-term efficacy and safety of the psychedelic in ...

Experts at HLTH Europe discussed how to ensure patients have trust in the EHDS to ensure a successful roll-out.

The China NMPA's CDE has granted approval to the IND application of InnoCare Pharma to initiate the trial of ICP-B794.

Biogen has commenced dosing in the Phase III PROMINENT trial, assessing the efficacy and safety of the felzartamab drug.

BioAtla has presented first-in-human Phase I study data of its anticancer therapy, BA3182, targeting those with metastatic adenocarcinoma.

Novartis’ Cosentyx (secukinumab) has failed to show any benefit in the Phase III study in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the GCAptAIN trial (NCT04930094), ...

Tango has dosed the first subject in the Phase I/II trial of TNG462 with Revolution Medicines' daraxonrasib or zoldonrasib.

INmune Bio said that a subset of Alzheimer's disease patients in the study showed clinical benefit from the therapy.

The trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.

Pfizer's recent trial termination makes it yet another company facing challenges with CD47 studies in oncology.

The HHS and the FDA have been ordered by US District Judge John Bates to restore the webpages on diversity following the court’s ruling.